Observational studyOncoimmunology2026

Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease.

Juan Zafra-Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.